Johnson & Johnson’s Covid Vaccine Cleared in the United States


Johnson & Johnson’s Covid Vaccine Cleared in United States

CORONAVIRUS – The United States this Saturday, February 27, granted an emergency authorization for Johnson & Johnson’s vaccine against Covid-19 for people aged 18 and over, the United States Medicines Agency (FDA) announced.

This single-dose vaccine called Janssen Covid-19, which can be stored at refrigerator temperatures, joins remedies from Pfizer / BioNTech and Moderna in the massive US vaccination campaign.

After studying in detail the data of clinical trials, conducted on more than 43,000 people, a committee of experts had recommended Friday the marketing of the vaccine of the American company.

From next week

At least three million doses of the “J&J” product are ready for distribution as early as next week, according to the US government. Johnson & Johnson has pledged to ship 100 million doses to the United States by the end of June.

With 600 million doses ordered in total from Pfizer and Moderna, the United States will already have, by the end of July, enough vaccine to immunize almost the entire population.

But the addition of those from Johnson & Johnson could further accelerate the vaccination campaign. In total, more than 72 million bites have already been carried out in the country most bereaved by the pandemic in absolute value.

The “J&J” vaccine, which injections have already started in South Africa, is a “viral vector” vaccine. It uses as support another low virulent virus, transformed to add genetic instructions from part of the virus responsible for Covid-19. Once in the cells, a typical SARS-CoV-2 protein is produced, educating the immune system to recognize it.

85.9% against severe forms

“After a rigorous analysis of the data, scientists and doctors at the FDA determined that the vaccine meets the FDA criteria for safety and efficacy for emergency clearance,” the director said in a statement. of the agency’s Biological Assessment and Research Center, Peter Marks.

In clinical trials, the vaccine’s efficacy was 85.9% against severe forms of Covid-19 in the United States, according to figures released by the FDA. All regions of the clinical trial combined, it was 66.1% against moderate forms of the disease, and overall “similar” for all categories of the population (ages, ethnic groups).

The most frequently observed side effects were pain at the injection site, headache, fatigue and muscle pain.

See also on The HuffPost: With the Covid-19, loneliness weighs you down? The Japanese have found a solution

Source: Le Huffington Post by

*The article has been translated based on the content of Le Huffington Post by If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!

*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.

*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!